MAYNE PHARMA GROUP ORD
Mayne Pharma board backs $672 million takeover bid from Cosette Pharma
Mayne Pharma (ASX: MYX) has received a takeover offer at a price of $7.40 per share from US-based pharmaceutical company Cosette Pharma, valuing the company at $672 million. Cosette has a portfolio of products in women’s health and dermatology and a long history of manufacturing complex dosage forms including topical creams, ointments, oral liquids/solutions and […]
Mayne Pharma forecasts up to $215m revenue for 1H25 as growth momentum continues
Mayne Pharma (ASX: MYX) has reported a forecast revenue of between $210 million and $215m for the first half of the 2025 financial year, reflecting growth of approximately 14% on the previous corresponding period (pcp). The company is also expecting to report underlying EBITDA of between $30m and $32m, representing an increase of almost 300% […]
Mayne Pharma and Mithra to commercialise next generation combined oral contraceptive
Specialty pharmaceutical company Mayne Pharma Group (ASX: MYX) and women’s health drug delivery company Mithra Pharmaceuticals SA have joined forces to commercialise a next generation combined oral contraceptive in Australia. The companies have signed an exclusive long-term licence and supply agreement to develop E4/DRSP, formulated to contain 15 milligrams of estetrol and 3mg of drospirenone. […]